Clinical Trials

27 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

9 enrolled

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

310 enrolled

Prostatic Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT04455750 2026-02-05

CASPAR

61 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Breast Neoplasms

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

60 enrolled

Hormone Sensitive Prostate Cancer

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Breast Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT03860987 2025-09-08

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

12 enrolled

Castrate Sensitive Prostate Cancer

NCT04181203 2025-07-30

CARLHA-2

490 enrolled

Prostatic Neoplasms

NCT05694819 2025-05-22

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

56 enrolled

Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT00544830 2025-05-07

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

29 enrolled 12 charts

PSA Level Greater Than Two

NCT03361735 2025-05-02

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled

Phase NA Active not recruiting

Prostate Adenocarcinoma

NCT02346253 2025-04-03

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

146 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

102 enrolled

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT04551495 2024-12-04

ROSALINE

65 enrolled

Carcinoma, Lobular

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT03423199 2024-03-22

PATHWAY

180 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05003752 2023-03-07

Hypo-Combi

40 enrolled

Prostatic Neoplasms, Radiation Injuries

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

788 enrolled 10 charts

Prostatic Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

10 enrolled